Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Stem Cell Opportunity: Taking a Stand when It's Too Early

This article was originally published in Start Up

Executive Summary

The degenerative diseases that are the target of new stem cell therapies represent many of the largest unmet clinical needs in medicine today. According to "Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets in the US, " a report recently published by Medtech Insight, in the future, stem cell therapies will hold a place in numerous markets, each with potential sales in the billions.

Related Content

Osiris/Genzyme Put Stem Cells On The Deal Map
Stem Cell Therapy Shown Safe For Most Myocardial Infarction Patients
Stem Cell Summit 2008: Moving from Process to Product
Scaffolds in Tissue Engineering
Stem Cell Therapies: Excitement Builds but Challenges Remain
Multiple Paths of Convergence in Tissue Engineering
Multiple Paths of Convergence in Tissue Engineering
Stem Cells: What's the Business Model?


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts